Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Semaglutide (Ozempic®) is recommended as an option for restricted use within NHS Wales for the treatment of insufficiently controlled type 2 diabetes mellitus in adults as an add-on therapy to oral antidiabetic medicines or basal insulin. Semaglutide (Ozempic®) is not recommended for use within NHS Wales as monotherapy when metformin is considered inappropriate due to intolerance or contraindications. |
|||
|
|||
Medicine details |
|||
| Medicine name | semaglutide (Ozempic®) | ||
| Formulation | 1.34 mg/ml solution for injection | ||
| Reference number | 1842 | ||
| Indication | Treatment of insufficiently controlled type 2 diabetes mellitus in adults as an add-on therapy to oral antidiabetic medicines or basal insulin. |
||
| Company | Novo Nordisk Ltd | ||
| BNF chapter | Endocrine system | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 1618 | ||
| NMG meeting date | 05/09/2018 | ||
| AWMSG meeting date | 17/10/2018 | ||
| Date of issue | 02/11/2018 | ||
| Date of last review | April 2022 | ||
| Further information This appraisal recommendation was reviewed in April 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations. |
|||